The aim of this study was to investigate the role of CYP2W1 and CYP2B6 SNPs as potential markers of response to mitotane treatment, providing more insights into a personalized mitotane therapy in patients affected by ACC. The gene discussed is CYP2W1; the disease is adrenal cortex carcinoma.